SEngine Precision Medicine Platform
AI-powered precision medicine platform for personalized healthcare
Platform · Cloud SaaSCompany source
Company profile
About SEngine Precision Medicine
SEngine Precision Medicine is a healthcare technology company operating in the precision medicine and genomics space. While detailed information about the company's specific offerings and approach is limited from the available website content, the company name and categorization suggest a focus on leveraging genomic data and precision medicine methodologies to deliver personalized healthcare solutions. The company appears to be positioned at the intersection of genomics, data analytics, and clinical applications, though specific product details, target markets, and technological approaches require further investigation. As a precision medicine company, SEngine likely works with healthcare providers, research institutions, or pharmaceutical companies to enable more targeted and personalized treatment approaches based on individual patient characteristics and genetic profiles.
Company description SEngine Precision Medicine official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at SEngine Precision Medicine?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
No clinical focus areas are currently listed.
Who it serves
No customer types are currently listed.
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing.NPJ precision oncology · May 18, 2023
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates.JCO precision oncology · Apr 1, 2023
Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma.Frontiers in oncology · Jan 1, 2023
Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL.Cancer research · Sep 16, 2022
Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer.The Journal of experimental medicine · Jun 6, 2022
Synthetic lethal kinases in Ras/p53 mutant squamous cell carcinoma.Oncogene · Jun 1, 2022
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from SEngine Precision Medicine
Recent articles published on SEngine Precision Medicine's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.